LS9 Selected as a Top 10 Venture-Backed Green Company by The Wall Street Journal
(GLOBE NEWSWIRE) -- LS9, Inc., a technology leader in the development of renewable and sustainable chemicals and fuels, today announced that the The Wall Street Journal selected the Company as one of the 2012 Top 10 Venture-Backed Green Companies.
BG Medicine, Inc. Appoints Charles H. Abdalian, Jr. as Chief Financial Officer
WALTHAM, Mass., Oct. 18, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that it has appointed Charles H. Abdalian, Jr., as the company's Executive Vice President, Chief Financial Officer. Mr.
Joule, LS9 and Novomer Named to the Global Cleantech 100 2012
Welcome to the Global Cleantech 100 2012
The Global Cleantech 100 represents innovation and highlights the companies most likely to make a significant market impact in the next 5-10 years
The OCS™ Lung Initial European Clinical Experience Featured in The Lancet
Andover, Mass., October 10, 2012, The Lancet has published the initial series of successful lung transplants demonstrating the feasibility and safety of using the Organ Care System™ (OCS™) Lung technology, at Hannover Medical Schoo
Keraflex® Keratoconus Treatment Study Begins in US
Hersh Vision Group is the first to offer this novel keratoconus treatment
Life Sciences Venture Funding Drops
In today’s economy, capital is much more difficult to raise, and the various sources of investment, from private angels to larger VC firms, are understandably much more cautious and conservative about where they place their money. “The economic recession made its impact on life sciences investments, as there have been negative returns on investments for the last 12 years.
LS9 Scales Up in Chemical Business As Biofuels Industry Re-Tools
The South San Francisco company LS9 recently produced five tons of industrial chemicals from plant sugars at a Florida demonstration facility, a step toward proving that its genetically engineered microbes can manufacture carbon compounds and fuels at a commercial scale.
T2 Biosystems Named a "Fierce 15" Medical Device and Diagnostic Company of 2012
LEXINGTON, Mass., Oct 02, 2012 (BUSINESS WIRE) -- T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012.
Shire scoops up Pervasis Therapeutics
By Galen Moore, Boston Business Journal